2023
Radiation Pneumonitis
Laird J, Decker R, Roberts K, Park H. Radiation Pneumonitis. In: Grippi M, Antin-Ozerkis D, Dela Cruz C, Kotloff R, Kotton C, Pack A (editors). Fishman’s Pulmonary Diseases and Disorders, 6th edition. New York: McGraw-Hill: 2023; p. 966-986.Chapters
2022
Early Laryngeal Cancer
Crosby T, Laird J, Park H, McWharter A. Early Laryngeal Cancer. In: Johnson J and Rosen C (editors). Bailey’s Head & Neck Surgery Otolaryngology, 6th Edition. Philadelphia: LWW: 2022; Chapter 141.Chapters
2021
Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer
Laird J, Leventhal J, Kanowitz J, Damast S. Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer. Practical Radiation Oncology 2021, 11: 448-452. PMID: 34157449, DOI: 10.1016/j.prro.2021.06.001.Peer-Reviewed Original ResearchDrivers of Medicare Spending: A 15-Year Review of Radiation Oncology Charges Allowed by the Medicare Physician/Supplier Fee-for-Service Program Compared With Other Specialties
Mokhtech M, Laird JH, Maroongroge S, Zhu D, Falit B, Johnstone PAS, Mantz CA, Ennis RD, Sandler HM, Dosoretz AP, Yu JB. Drivers of Medicare Spending: A 15-Year Review of Radiation Oncology Charges Allowed by the Medicare Physician/Supplier Fee-for-Service Program Compared With Other Specialties. International Journal Of Radiation Oncology • Biology • Physics 2021, 110: 322-327. PMID: 33412264, DOI: 10.1016/j.ijrobp.2020.12.051.Peer-Reviewed Original Research
2020
Ovarian Cancer
Laird J, Tymon-Rosario J, Damast S. Ovarian Cancer. 2020 DOI: 10.1891/9780826155146.0026.ChaptersEndometrial Cancer
Laird J, An Y, Damast S. Endometrial Cancer. 2020 DOI: 10.1891/9780826155146.0027.ChaptersCervical Cancer
Laird J, Young M, Damast S. Cervical Cancer. 2020 DOI: 10.1891/9780826155146.0028.ChaptersVulvar Cancer
Laird J, Young M, Damast S. Vulvar Cancer. 2020 DOI: 10.1891/9780826155146.0030.Chapters
2019
Positron-Emission Tomographic Imaging of a Fluorine 18–Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient–Derived Xenografts
Laird J, Lok B, Carney B, Kossatz S, de Stanchina E, Reiner T, Poirier J, Rudin C. Positron-Emission Tomographic Imaging of a Fluorine 18–Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient–Derived Xenografts. Journal Of Thoracic Oncology 2019, 14: 1743-1752. PMID: 31195178, PMCID: PMC6764879, DOI: 10.1016/j.jtho.2019.05.032.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisCell ProliferationFemaleFluorine RadioisotopesHumansLung NeoplasmsMiceMice, Inbred NODMice, SCIDPhthalazinesPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPositron-Emission TomographyRadiopharmaceuticalsSmall Cell Lung CarcinomaTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsPatient-derived xenograftsPositron emission tomographicPARP inhibitorsTherapeutic efficacyTarget engagementPositron emission tomographic imagingDifferential therapeutic efficacyTumor radiotracer uptakeTumor growth inhibitionEnzyme-linked immunosorbentDose-dependent mannerFluorine-18Oral talazoparibMultiple dosesSingle dosesTotal tumorsPolymerase-1 (PARP-1) inhibitorsPET uptakeRadiotracer uptakeInhibitor of polyIndividual tumorsPET/Drug efficacyTalazoparib treatmentPromising therapeutics
2018
Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies
Ma J, Laird J, Chau K, Chelius M, Lok B, Yahalom J. Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies. Cancer Medicine 2018, 8: 58-66. PMID: 30597769, PMCID: PMC6346231, DOI: 10.1002/cam4.1844.Peer-Reviewed Original ResearchConceptsLangerhans cell histiocytosisAdult LCH patientsAdditional malignanciesLCH patientsLCH diagnosisCell histiocytosisSolid malignanciesHigh prevalenceSingle institution experienceCause of malignancyYears of ageOncologic historyConsecutive patientsMedian ageHistiocyte proliferationHematologic malignanciesRare disorderLCH treatmentRare diseasePatientsMalignancySolid tumorsTumorigenic agentsHistiocytosisCohortASO Author Reflections: Breast Cancer Local Recurrence Versus New Primary-Clinical Predictors and Prognostic Implications.
Laird J, Braunstein LZ. ASO Author Reflections: Breast Cancer Local Recurrence Versus New Primary-Clinical Predictors and Prognostic Implications. Ann Surg Oncol 2018, 25: 648-649. PMID: 30306376, DOI: 10.1245/s10434-018-6889-4.Commentaries, Editorials and LettersReply to "Questions About In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy".
Laird J, Braunstein LZ. Reply to "Questions About In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy". Ann Surg Oncol 2018, 25: 3779. PMID: 29270878, DOI: 10.1245/s10434-017-6286-4.Commentaries, Editorials and LettersTalazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts
Laird J, Lok B, Ma J, Bell A, de Stanchina E, Poirier J, Rudin C. Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts. Clinical Cancer Research 2018, 24: 5143-5152. PMID: 29945991, PMCID: PMC6742772, DOI: 10.1158/1078-0432.ccr-18-0401.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsCell Line, TumorCell SurvivalDisease Models, AnimalDNA Breaks, Double-StrandedDose-Response Relationship, DrugHumansPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsRadiation ToleranceRadiation-Sensitizing AgentsRadiation, IonizingSmall Cell Lung CarcinomaXenograft Model Antitumor AssaysConceptsSmall cell lung cancerSCLC cell linesClonogenic survival assaysCell linesPatient-derived xenograft modelsPARP inhibitionShort-term viability assaysDoses of veliparibCell lung cancerClin Cancer ResEfficacy of radiotherapyTumor growth inhibitionViability assaysAggressive malignancyLung cancerPDX modelsNovel therapiesSCLC cellsXenograft modelSingle agentPARP inhibitorsCancer ResTalazoparibSurvival assaysContribution of PARP
2017
Outcome After Radiation Therapy for Langerhans Cell Histiocytosis Is Dependent on Site of Involvement
Laird J, Ma J, Chau K, Chelius M, Shi W, Zhang Z, Lok B, Yahalom J. Outcome After Radiation Therapy for Langerhans Cell Histiocytosis Is Dependent on Site of Involvement. International Journal Of Radiation Oncology • Biology • Physics 2017, 100: 670-678. PMID: 29413280, PMCID: PMC5806138, DOI: 10.1016/j.ijrobp.2017.10.053.Peer-Reviewed Original ResearchConceptsRadiation therapyLocal failureLocal recurrenceMultisystem involvementBone lesionsHigh riskSite of involvementAdditional treatment modalitiesLymph node lesionsLangerhans cell histiocytosisSite of lesionRadiologic responseMedian dosePatient demographicsIrradiated lesionsLymph nodesMedian ageNode lesionsLCH patientsMultisystem diseaseCell histiocytosisTreatment modalitiesMultiple time pointsBrain lesionsSkin lesionsImpact of an In Situ Component on Outcome After In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy
Laird J, Lok B, Siu C, Cahlon O, Khan A, McCormick B, Powell S, Cody H, Wen H, Ho A, Braunstein L. Impact of an In Situ Component on Outcome After In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy. Annals Of Surgical Oncology 2017, 25: 154-163. PMID: 29094250, PMCID: PMC5827945, DOI: 10.1245/s10434-017-6209-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCarcinoma, LobularDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateMastectomy, SegmentalMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingNeoplasms, Second PrimaryProportional Hazards ModelsRadiotherapy, AdjuvantSurvival RateConceptsDisease-free survivalBreast-conserving therapyBreast tumor recurrenceTrue recurrenceNew primarySitu componentOverall survivalTumor sizeTumor recurrenceFive-year disease-free survivalTR groupCox proportional hazards regression modelLower disease-free survivalWorse disease-free survivalProportional hazards regression modelsSimultaneous distant metastasesKaplan-Meier methodHazards regression modelsLog-rank testAxillary surgeryDFS eventsNode involvementLymphovascular invasionMargin statusUnresectable recurrenceUnravelling the biology of SCLC: implications for therapy
Sabari J, Lok B, Laird J, Poirier J, Rudin C. Unravelling the biology of SCLC: implications for therapy. Nature Reviews Clinical Oncology 2017, 14: 549-561. PMID: 28534531, PMCID: PMC5843484, DOI: 10.1038/nrclinonc.2017.71.Peer-Reviewed Original ResearchConceptsBiology of SCLCHigh-grade neuroendocrine tumorsPARP inhibitor veliparibImmune checkpoint blockadeEncouraging clinical activityPoor overall survivalHigh mutational burdenImmune checkpoint proteinsZeste homologue 2Antibody-drug conjugatesOverall survivalRovalpituzumab tesirineLung cancerNeuroendocrine tumorsClinical trialsClinical activityMutational burdenNew therapiesTherapeutic targetingProtein 3SCLCHomologue 2PatientsPromising activityTherapy